Business
NovaBay Pharmaceuticals, Inc. Retains The Investor Relations Group of New York
IRG to Communicate the Company's Clinical Development Programs EMERYVILLE, CALIF., November 20 /C...
About this update from Niobay Metals Inc.
[{"type":"text","content":"\n\n\n\nIRG to Communicate the Company's Clinical Development Programs\n\n\nEMERYVILLE, CALIF., November 20 /CNW/ - NovaBay Pharmaceuticals, Inc.\n(Amex & TSX: NBY), a biopharmaceutical company focused on developing\ninnovative product candidates targeting the treatment or prevention of a wide\nrange of infections in hospital and non-hospital environments, has retained\nthe New York City-based The Investor Relations Group, Inc. (IRG), to serve as\nits investor relations and corporate communications firm.\n\n\n"Having recently completed our initial public offering, we remain focused\non moving forward with our clinical development of non-antibiotic\nanti-infective products targeting the treatment or prevention of a wide range\nof infections in hospital and community environments," said Ron Najafi, Ph.D.,\nChairman and Chief Executive Officer of NovaBay. "With leading pharmaceutical\npartners and several product candidates in the pipeline, we believe The\nInvestor Relations Group will play an integral role in communicating NovaBay's\nmessage to the investment community and the general media."\n\n\nAbout The Investor Relations Group, Inc.\n\n\nThe Investor Relations Group, Inc. (IRG) offers a full-service corporate\ncommunications program designed to suit the many unique needs of small-cap\ncompanies. The program utilizes a proprietary, targeted approach to reach\ninstitutional investors, analysts, and the media-at-large. For further\ninformation, please visit the company's website at\nwww.investorrelationsgroup.com.\n\n\nAbout NovaBay\n\n\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on\ndeveloping innovative product candidates targeting the treatment or prevention\nof a wide range of infections in hospital and non-hospital environments.\nNovaBay has discovered and is developing a class of antimicrobial compounds,\nwhich it has named Aganocide compounds, which are based upon small molecules\nthat are generated by white blood cells that defend the body against invading\npathogens. NovaBay believes that Aganocide compounds could form a platform on\nwhich to create a variety of products to address differing needs in the\ntreatment and prevention of bacterial and viral infections, including\nMethicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a\nlicensing and res...